Visiox Pharma Appoints Industry Leader Ryan S. Bleeks as Chief Executive Officer… – Press Release


Ophthalmic Industry Leader Joins to Accelerate the Organization in Anticipation of Two Near-Term Product Launches

TARRYTOWN, N.Y., May 17, 2022 /PRNewswire/ — Visiox Pharma, LLC., a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced the appointment of Ryan S. Bleeks as Chief Executive Officer.

“We are excited to have Ryan join Visiox at this critical time for the organization,” said Michael Derby, Visiox’s Founding Investor and Executive Chairman. “His proven leadership in building teams, company infrastructure and executing successful launch strategies in the ophthalmics space will be instrumental as we accelerate our path towards commercialization.”

“I am thrilled to build a business for the future that brings meaningful solutions to providers and patients while establishing Visiox’s commitment to Ophthalmics,” said Mr. Bleeks. “As we prepare for launch, we will continue to build a robust pipeline though the acquisition of early and late-stage assets.”

Most recently Mr. Bleeks was the Vice President of Sales, Sales Training and Sales Operations at RVL Pharmaceuticals plc, where he was responsible for building the infrastructure, sales force and launch execution of UPNEEQâ, the first product to treat acquired blepharoptosis in adults with an innovative prescription cash pay strategy. Prior, he was the National Sales Director at Sun Pharma responsible for the successful launches of CEQUAä and XELPROSä. Mr. Bleeks brings more than two decades of commercial experience, built on deep relationships in ophthalmology and optometry, which he established while launching more than 12 products in the eyecare space.

About Visiox

Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in…